STAT+: Wagering on FDA changes, Regenxbio will submit Duchenne gene therapy for approval

🇺🇸 STAT News Health (US) —
STAT+: Wagering on FDA changes, Regenxbio will submit Duchenne gene therapy for approval

AI Summary

Regenxbio is set to submit its Duchenne gene therapy for FDA approval following regulatory guidance. The move signifies progress in gene therapy development for muscular dystrophy treatment.

Regenxbio plans to submit its Duchenne gene therapy for FDA approval, just a month after it said that regulators wanted to see another trial.

Markets Deals Health AI & Tech Regenxbio FDA approval Duchenne gene therapy muscular dystrophy clinical trials biotech

Read original source →